
Chris Varma, Frontier Medicines CEO (file photo)
AbbVie eyes cancer, immunology in latest protein degradation pact, handing Frontier Medicines $55M upfront
Two years after tiptoeing into the protein degradation space with a discovery pact centered on neurodegeneration, AbbVie is wading deeper to explore the more common applications in cancer and immunological diseases.
The pharma giant is handing Frontier Medicines $55 million upfront to get things started while promising to reimburse its preclinical R&D costs. In addition to drug candidates that target E3 ligases — a key member of the body’s natural degradation system — Frontier will also be scouting small molecule binders to targets.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters